Real-time Estimate Cboe Europe 07:31:31 2024-03-28 am EDT 5-day change 1st Jan Change
1,006 GBX -1.90% Intraday chart for Smith & Nephew Plc -2.25% -6.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Smith & Nephew CFO designate John Rogers to start next week AN
Smith & Nephew CFO to Take Office in April MT
Smith & Nephew plc Announces CFO Changes CI
Smith & Nephew plc Announces Board Changes CI
Smith & Nephew Signs Up as Official Partner for UFC MT
Smith+Nephew Teams Up with Ufc to Be First-Ever Preferred Sports Medicine Technology Partner CI
Smith & Nephew prices USD1 billion in debt notes AN
Smith & Nephew plc Completes the Pricing of Usd 350,000,000 5.150% Notes Due 2027 and Usd 650,000,000 5.400% Notes Due 2034 CI
Smith & Nephew Prices Offering of Notes due 2027, 2034 MT
UK's Smith & Nephew Mulls Raising Pay for US Execs MT
Jefferies says buy BP; UBS says buy Compass AN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat MT
SMITH & NEPHEW : Strong ‘proof of execution’ to end FY23 Alphavalue
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Smith & Nephew Signs Research Deal With US Army Institute of Surgical Research MT
Barclays Lifts Smith & Nephew PT, Maintains Equalweight Rating MT
Berenberg, JPMorgan raise price target for IHG AN
UK’s Shop Price Inflation Hits Two-year Low; Stocks Flat MT
Smith & Nephew 2023 Adjusted Earnings, Revenue Rise MT
Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024 CI
Smith & Nephew plc Provides Earnings Guidance for 2024 CI
British investors await key economic data amid cautious trading Our Logo
Smith & Nephew revenue and profit rise; keeps dividend unchanged AN
Stocks drift higher; Smith & Nephew performs well AN
London stocks gain on miners, earnings boost RE
Chart Smith & Nephew Plc
More charts
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipments. Net sales break down by activity sector as follows: - orthopedic surgery (40.5%): primarily orthopedic implants (hips, knees and shoulders) ; - sports medicine, arthroscopy and cervicofacial surgery (30.5%): surgery and damaged tissue repair products and instruments, visualization products, etc.; - wound care (29%): skin grafts for major burns victims, treatments for leg ulcers, etc. The United States accounts for 53% of net sales.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
13.18 USD
Average target price
16.51 USD
Spread / Average Target
+25.34%
Consensus
  1. Stock
  2. Equities
  3. Stock Smith & Nephew Plc - London S.E.
  4. News Smith & Nephew Plc
  5. UBS Trims Smith & Nephew's PT, Maintains Neutral Rating